Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell Membranes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Cell Membranes. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2017-005082-47 Sponsor Protocol Number: HUS/1209/2017 Start Date*: 2018-09-24
    Sponsor Name:Sydän- ja keuhkokeskus, HUS
    Full Title: Repolarization study in LQTS patients
    Medical condition: Long QT syndrome (LQTS) is a hereditary arrhythmia disease. It causes disturbances to the ion flow through cell membranes of cardiomyocytes. These disturbances can sometimes seen in an electrocardi...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002380-90 Sponsor Protocol Number: IVN3DIALYSE Start Date*: 2005-09-26
    Sponsor Name:Nyremedicinsk afdeling, Aalborg Sygehus
    Full Title: Effekten af intravenøs infusion af n-3 polyumættede fedtsyrer på risikomarkører for pludselig hjertedød hos hæmodialysepatienter
    Medical condition: Chronic renal failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005486-40 Sponsor Protocol Number: CELOPHIN Start Date*: 2022-07-22
    Sponsor Name:FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE
    Full Title: Phase IIa multicenter clinical trial to determine the feasibility and safety of the use of adipose-derived mesenchymal stem cells (ASC) in the treatment of patients with cicatricial conjunctivitis ...
    Medical condition: Cicatricial conjunctivitis associated with Lyell's syndrome, Stevens-Johnson syndrome and mucous membrane pemphigoid with ocular involvement.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005582-36 Sponsor Protocol Number: SIM-07-003 Start Date*: 2008-04-07
    Sponsor Name:DEFIANTE FARMACEUTICA,LDA
    Full Title: A RANDOMIZED MULTICENTRE PHASE II STUDY TESTING TOLERABILITY AND EFFICACY ON SURROGATE ENDPOINTS (LIPID PROFILE, VASCULAR INFLAMMATORY MARKERS AND THROMBOGENESIS) OF SIMVAPUFA FORMULATION (ASSOCIAT...
    Medical condition: For this study, patients with acute coronary syndrome STEMI (ST-Elevation Myocardial Infarction and NSTEMI (Non-ST-Elevation Myocardial Infarction), occurred within the previous 72 hours with posit...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016880-13 Sponsor Protocol Number: ITU version1 19/10/2009 Start Date*: 2011-03-11
    Sponsor Name:UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST
    Full Title: RANDOMIZED CONTROLLED TRIAL OF THE EFFECTS OF PARENTERAL FISH OIL EMULSION IN CRITICALLY ILL SEPTIC PATIENTS IN THE INTENSIVE CARE UNIT
    Medical condition: Sepsis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004247-24 Sponsor Protocol Number: CCRG13-003 Start Date*: 2015-01-27
    Sponsor Name:Antwerp University Hospital (UZA)
    Full Title: Translational stem cell research in ophthalmology - regenerating the anterior cornea through standardized transplantation of limbal epithelial stem cells: a phase II multicenter trial
    Medical condition: Primary and secondary Limbal Stem Cell Deficiencies
    Disease: Version SOC Term Classification Code Term Level
    17.1 10042613 - Surgical and medical procedures 10069798 Amniotic membrane graft PT
    17.1 10015919 - Eye disorders 10072138 Limbal stem cell deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003302-40 Sponsor Protocol Number: WO40242 Start Date*: 2018-04-10
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY AFTER DEFINITIVE LOCAL THERAPY IN PATIENTS WITH HIGH-RISK LOCA...
    Medical condition: Locally advanced squamous cell carcinoma of the head and neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) PL (Ongoing) FR (Completed) BE (Completed) PT (Completed) HU (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003917-83 Sponsor Protocol Number: CHAVANET-BASILEA-2016 Start Date*: 2017-08-16
    Sponsor Name:CHU de DIJON
    Full Title: Open and exploratory trial to investigate the pharmacokinetic of ceftobiprole medocaril in patients with CSF device
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027199 Meningitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000605-72 Sponsor Protocol Number: CB+MSCforEB Start Date*: 2014-02-06
    Sponsor Name:Universitair Medisch Centrum Utrecht
    Full Title: Unrelated cord blood transplantation after reduced toxicity conditioning with mesenchymal stromal cell co-infusion in patients with severe epidermolysis bullosa
    Medical condition: The source population consists of patients referred to or within the UMC Groningen because they have diagnosed clinically and genetically severe generalized RDEB.
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-004854-97 Sponsor Protocol Number: A8851019 Start Date*: 2008-01-15
    Sponsor Name:Pfizer Ltd
    Full Title: OPEN-LABEL, NON-COMPARATIVE, STUDY OF INTRAVENOUS ANIDULAFUNGIN, FOLLOWED OPTIONALLY BY ORAL VORICONAZOLE OR FLUCONAZOLE THERAPY, FOR TREATMENT OF DOCUMENTED CANDIDEMIA/INVASIVE CANDIDIASIS IN INTE...
    Medical condition: CANDIDAEMIA/INVASIVE CANDIDIASIS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064954 Invasive candidiasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) FR (Completed) BE (Completed) PT (Completed) NL (Completed) IT (Completed) SK (Completed) PL (Completed) CZ (Completed) DK (Completed) HU (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-001903-36 Sponsor Protocol Number: CC-4047-MM-013 Start Date*: 2014-01-20
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 2 MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF POMALIDOMIDE (CC-4047) IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MY...
    Medical condition: Refractory or refractory multiple myeloma (MM) in patients with moderate or severely impaired renal function.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GR (Completed) ES (Completed) GB (GB - no longer in EU/EEA) NL (Completed) AT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002193-40 Sponsor Protocol Number: DT-001-R-004 Start Date*: 2018-04-04
    Sponsor Name:Afyx Therapeutics A/S
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Study to Assess the Safety and Efficacy of Three Doses of Clobetasol Propionate when Administered Intra-orally Twice Daily in...
    Medical condition: Oral Lichen Planus (OLP). OLP is a common, chronic mucosal disease associated with a cell-mediated immunological dysfunction and characterized by exacerbations of inflammation, which can lead to ul...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10030983 Oral lichen planus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003832-19 Sponsor Protocol Number: RigosertibforRDEB-SCC Start Date*: 2017-12-11
    Sponsor Name:Gemeinn. Salzburger Landeskliniken BetriebsGesmbH, University Hospital for Dermatology, EB-House Austria
    Full Title: A Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients with Recessive Dystrophic Epidermolysis bullosa associated Locally Advanced/Metastatic Squamous Cell Carcinoma
    Medical condition: Recessive dystrophic epidermolysis bullosa (RDEB) is a severe genodermatose caused by mutations in COL7A1, characterized by generalized skin blistering and involvement of mucous membranes. Aggressi...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002723-42 Sponsor Protocol Number: HH1222 Start Date*: 2013-09-11
    Sponsor Name:Rigshospitalet
    Full Title: Electrochemotherapy of Head and Neck Cancer
    Medical condition: Head and Neck Cancer. We would like to investigate the possible use of electrochemotherapy in recurrent head and neck cancer. Surgery and radiotherapy, with the possible addition of chemotherapy, c...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004865 10068476 Electrochemotherapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000308-12 Sponsor Protocol Number: P150941J Start Date*: 2020-11-06
    Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Full Title: « Mesenchymal stromal cells treatment in Lyell syndrome: A pilot phase 1-2 open trial”
    Medical condition: Patients: Adults diagnosed with SJS-TEN with at least 10% of body surface area involved.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10025166 Lyell syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005330-14 Sponsor Protocol Number: VAC31518COV2004 Start Date*: 2021-04-06
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: An Open-label, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants.
    Medical condition: Healthy Pregnant Volunteers (Prevention of SARS-CoV-2-mediated COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004940-27 Sponsor Protocol Number: AIC316-03-II-01(Phase3) Start Date*: Information not available in EudraCT
    Sponsor Name:AiCuris Anti-infective Cures GmbH
    Full Title: A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in ...
    Medical condition: Acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjects
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Ongoing) BE (Ongoing) IT (Ongoing) GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010520-25 Sponsor Protocol Number: AMR-01-01-0016 Start Date*: 2009-12-08
    Sponsor Name:Amarin Pharma Inc.
    Full Title: A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With an Open-Label Extension to Evaluate the Efficacy and Safety of AMR101 in Patients With Fasting Triglycer...
    Medical condition: Hypertriglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014486 Elevated triglycerides HLT
    9.1 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) DK (Prematurely Ended) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-018077-31 Sponsor Protocol Number: 012010 Start Date*: 2010-11-25
    Sponsor Name:St. Anna Kinderkrebsforschung/CCRI
    Full Title: A PHASE I/II DOSE SCHEDULE FINDING STUDY FOR CH14.18/CHO CONTINUOUS INFUSION COMBINED WITH SUBCUTANEOUS ALDESLEUKIN (IL-2) IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSING NEUROBLASTOMA
    Medical condition: High-risk neuroblastoma patients having received at least one previous high dose treatment followed by stem cell rescue after conventional therapy fulfilling one of the following criteria: • Prima...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Ongoing) ES (Ongoing) DE (Ongoing) IT (Ongoing) GB (GB - no longer in EU/EEA) IE (Ongoing) PL (Completed) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004616-37 Sponsor Protocol Number: ML29966 Start Date*: 2016-08-03
    Sponsor Name:GENENTECH Inc.
    Full Title: An open-label, multicenter, biomarker study to explore the mechanism of action of ocrelizumab and B-cell biology in patients with relapsing multiple sclerosis or primary progressive multiple sclero...
    Medical condition: Relapsing Multiple Sclerosis (RMS)/Primary Progressive Multiple Sclerosis (PPMS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:28:43 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA